This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (8)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

David A. Grimes, MD

JAMA. 1993;270(23):2855-2856.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Ovarian cancer remains the deadliest gynecologic malignancy in the United States, killing more women each year than cervical and endometrial cancers combined. Despite aggressive operations and intensive chemotherapy, the 5-year survival rate is less than 40%.¹ Complications such as bowel obstruction, inanition, ascites, and pleural effusions can make this a wretched way to die. Hence, the finding of Hankinson et al² in this issue of JAMA is heartening: tubal sterilization may protect against this malignancy.

See also p 2813.

The Nurses' Health Study is not the first to observe this protection.^3-5 The importance of this research, however, stems from its design: a large, prospective cohort study. Cohort studies avoid some of the vexing problems of case-control studies, such as selection of an appropriate control group. Ascertainment bias is unlikely to have accounted for these results. The respondents were knowledgeable health professionals, and medical records confirmed reported illness. While . . . [Full Text PDF of this Article]

Author Affiliations
From the Program in Reproductive Epidemiology, Department of Obstetrics, Gynecology and Reproductive Sciences, and the Department of Epidemiology and Biostatistics, University of California, San Francisco.

Footnotes
Reprints not available.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?